植株密度對袋耕‘花蓮亞蔬五號’番茄生長與產量之影響

In bag culture of tomato, the stem diameter, plant dry weight and 8 plants with 3 cultures of fruit per bag was less than those of 6 plants with 3 clusters of fruit and 6 plants with 6 clusters of fruit. Th eplant height and the first to third in florescence were significant increased. But it did not affect the position of inflorescence node. There was no significant difference on days to first flower, number of flowers per cluster, and early yield when plant density was increased to 8 plants per bag. Eight plants with 3 clusters of fruits per bag showed smaller single fruit weight, but the ratio of large and medium size fruit was over 80% that was not significantly different compared to control. The control had the highest yield per plant, followed by 3 clusters 6 plants per bag and 3clusters of 8 plants per bag was the lowest. In comparison of harvesting first 3 clusters per plant per bag, the 8 plants had higher yield, early yield and total fruit number than the 6 plants. The soluble solid in fruit was decreased in 8 plants per bag.'花蓮亞蔬五號'番茄袋植每袋種八株收三花序果實之莖徑、植株乾重與鮮重低於種六株收三花序果實及對照組六植株採收六花序果實者，其株高明顯徒長，第一~三花序著果高度提高，但著果節位並無顯著差異。栽培密度提高至八株者對始花日、開花數影響不顯著，每袋種八株者之單果重比六株者小，大果與中果佔80%以上，與對照組間無明顯差異。單株產量以對照組產量最高，其次為每袋種六株留三花序，而每袋種八株者最低。比較三段花序果實之每袋產量、單位面積產量與每袋果實數以種八株者比種六株者高，果實可溶性固形物則較低

茄子砧木嫁接番茄之產生情形

Grafted tomato cv. 'Known-You 301' using eggplant cv. 'Hsiao-Tan','KSA22','Akanasu' and 'VF(F1)' as rootstocks were grown in autumn and spring crop, and cv. 'Taichung-AVRDC 4' in summer crop. Yield was not increased on grafted tomato cv. 'Known-You 301' using four eggplant rootstock in autumn crop. Grafted tomato cv. 'Known-You 301' using 'Hsiao-Tan' and 'VF(F1)' had higher yield than ungrafted tomato, but not reached significant level in spring crop. Result showed survival rate of grafted tomato cv. 'Taichung-AVRDC 4' were over than 88.3％, and their rate of fruit setting, single fruit weight, number of harvested fruits and plot yield were also increased in summer crop. However, low rate of fruit setting, single fruit weight, number of harvested fruits and plot yield were observed in both grafted and ungrafted tomato. The grafted tomato cv. 'Red Crown' and 'Tainan-AVRDC 6' using eggplant 'EG203' on field trial in summer crop, 2001.秋作番茄嫁接四種茄子砧木對大果番茄'農友 301'無增產效果；春作以'小丹茄'及'VF(F1)'為砧木時，產量雖較未嫁接株稍高，但增產效果不顯著。夏作結果顯示，'小丹茄'、'KSA22'、'赤茄'及'VF(F1)'等四種茄子嫁接'台中亞蔬4號'大果番茄之田間存活率達88.3以上，也顯著提高著果率、小區產量、採收果數及果重；嫁接與未嫁接株均呈著果率及產量低，採收果數少、果實小。90年夏季以'VF(F1)'為砧木，與現行推廣茄子'EG203'砧木相比較，證明目前番茄栽培使用茄子'EG203'砧木對'紅冠'及小果番茄'台南亞蔬6號'均增具增產效果，且'VF(F1)'優於'EG203'砧木

穴格容積對小白菜穴盤苗生育之影響

Pak-choi cv. 'Dai Tokyo' were sown in 72, 128 and 288-cell plug tray to study the cell sizes effects on seedling growth. Results indicated that, no significant difference on the fresh weigh, dry weight, leaf number, leaf area and root length among different cell sizes at early stages, However, the difference among treatments increased and became significant after 12 days of sowing. Seedlings in 72-cell plugs showed the best growth. The root/shoot ratios was found higher on seedlings in 288-cell plugs than those in 72-cell and 128 cells. The relative growth rates of roots and shoot were also found higher at early growth stage and decreased as seedling ages increased. Both the seedlings in 72 and 128-cell plug had the similar trends in plastchron index values, but that of the seedlings in 288-cell plugs was significantly lower.本試驗探討'大東京'小白菜於72、128及288格三種穴盤育苗對幼苗生育之影響，結果顯示小白菜幼苗之單株鮮重、乾重、本葉數、葉面積、葉長、根鮮重、乾重及根長等皆與穴格容積成正相關，且與播種後天數呈二次回歸正相關。播種後9-12天，在不同穴盤間並無顯著差異，隨著播種後天數增加，差異逐漸加大，以在72格穴盤有最佳生育，Plastochron Index(PI)值在72及128穴格趨勢相似，而288穴格為最低。'大東京'小白菜之地下部/地上部比以288穴格者較72及128穴格者高。地上部及根部鮮重之相對生長速率，在播種後初期成最高值，隨播種後天數增加相對生長速率逐漸降低。288穴格苗株在播種後21天之相對生長速率較72及128穴格者小，其後差異減少不顯著

不同灌溉水溫對番茄苗生育之影響

本研究以'花蓮亞蔬五號'番茄為材料，調查不同水溫、植株部位、冷水灌溉時間對番茄苗矮化效果及其品質之影響，其目的為建立冷水灌溉矮化番茄苗之系統，以作為種苗產業之應用的參考依據，並作為深入研究矮化苗之基礎資訊。試驗結果顯示當灌溉水溫較室溫水愈低(5°C)或愈高(65°C)均可抑制番茄苗莖伸長，以冷水處理(5°C)能獲得較高莖硬度(g/mm)及壯苗指數(seedhng index;地上部乾物重/株高比值)之番茄苗。冷水處理主要抑制番茄苗之部位為第一節間莖長。冷水灌溉時間於每日清晨(8:00)進行較中午(13:00)及下午(16:00)能夠獲得更矮之植株;每日植株最大生長速率為夜晚至清晨期間。冷水處理四週後，矮化植株的效果最佳，且冷水處理之溫度愈低或處理持續時間愈長，矮化植株效果愈明顯。冷水澆施至栽培介質內，介質土溫能夠在60-90秒內降至最低點，土溫回復至正常溫度約需60分鐘;葉溫鞍上溫變化程度大且葉片回溫時間較介質為短。綜合上述結果顯示5°C冷水灌溉能夠有效的矮化番茄苗及提升種苗品質，可作為種苗產業之參考及應用。In this study,‘Hwalien Yasu No.5'tomato was used to study the effects of different temperatures of irrigation water, parts of plant, timing of irrigation on the shortening and quality of plg-seedling. The purposes of this study were to establish the cold-water irrigation system for plug-seedlings production, and to provide the basic knowledge of shortening seedling for advanced study. The results indicated that shortest seedling was found in the seeding irrigated with the lowest (5∘C) or highest (65∘C) water temperature.However, highest stem strength and seedling index was only found in the seedling irrigated with the 5∘C water. Decrease in the length of first internode was primary responsible for the shortening seedling by cold-water irrigation.Irrigation of cold water at the morning (8:00) or evening (16:00) showed the best results in shortening seedling. After the cold water irrigation, the soil temperature drop to minimum within 60 to 90 sec, and recovered to the room temperature after 60 min. Longer period of cold-water irrigation and lower the cold-water temperature resulted shorter the seedlings. In conclusion, cold-water irrigation system for plug-seedlings production could apply in the commercial usages

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries(1,2). However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world(3) and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health(4,5). However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular riskchanged from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.Peer reviewe

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

Summary Background Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents. Methods For this pooled analysis, we used a database of cardiometabolic risk factors collated by the Non-Communicable Disease Risk Factor Collaboration. We applied a Bayesian hierarchical model to estimate trends from 1985 to 2019 in mean height and mean BMI in 1-year age groups for ages 5–19 years. The model allowed for non-linear changes over time in mean height and mean BMI and for non-linear changes with age of children and adolescents, including periods of rapid growth during adolescence. Findings We pooled data from 2181 population-based studies, with measurements of height and weight in 65 million participants in 200 countries and territories. In 2019, we estimated a difference of 20 cm or higher in mean height of 19-year-old adolescents between countries with the tallest populations (the Netherlands, Montenegro, Estonia, and Bosnia and Herzegovina for boys; and the Netherlands, Montenegro, Denmark, and Iceland for girls) and those with the shortest populations (Timor-Leste, Laos, Solomon Islands, and Papua New Guinea for boys; and Guatemala, Bangladesh, Nepal, and Timor-Leste for girls). In the same year, the difference between the highest mean BMI (in Pacific island countries, Kuwait, Bahrain, The Bahamas, Chile, the USA, and New Zealand for both boys and girls and in South Africa for girls) and lowest mean BMI (in India, Bangladesh, Timor-Leste, Ethiopia, and Chad for boys and girls; and in Japan and Romania for girls) was approximately 9–10 kg/m2. In some countries, children aged 5 years started with healthier height or BMI than the global median and, in some cases, as healthy as the best performing countries, but they became progressively less healthy compared with their comparators as they grew older by not growing as tall (eg, boys in Austria and Barbados, and girls in Belgium and Puerto Rico) or gaining too much weight for their height (eg, girls and boys in Kuwait, Bahrain, Fiji, Jamaica, and Mexico; and girls in South Africa and New Zealand). In other countries, growing children overtook the height of their comparators (eg, Latvia, Czech Republic, Morocco, and Iran) or curbed their weight gain (eg, Italy, France, and Croatia) in late childhood and adolescence. When changes in both height and BMI were considered, girls in South Korea, Vietnam, Saudi Arabia, Turkey, and some central Asian countries (eg, Armenia and Azerbaijan), and boys in central and western Europe (eg, Portugal, Denmark, Poland, and Montenegro) had the healthiest changes in anthropometric status over the past 3·5 decades because, compared with children and adolescents in other countries, they had a much larger gain in height than they did in BMI. The unhealthiest changes—gaining too little height, too much weight for their height compared with children in other countries, or both—occurred in many countries in sub-Saharan Africa, New Zealand, and the USA for boys and girls; in Malaysia and some Pacific island nations for boys; and in Mexico for girls. Interpretation The height and BMI trajectories over age and time of school-aged children and adolescents are highly variable across countries, which indicates heterogeneous nutritional quality and lifelong health advantages and risks

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings